tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

VRCA Stock Latest News

Verrica Pharmaceuticals price target raised to $14 from $13 at H.C. Wainwright
The FlyVerrica Pharmaceuticals price target raised to $14 from $13 at H.C. Wainwright
1d ago
VRCA
Verrica Pharmaceuticals sees cash runway into 1Q25
PremiumThe Fly
Verrica Pharmaceuticals sees cash runway into 1Q25
2d ago
VRCA
Verrica Pharmaceuticals reports Q1 adjusted EPS (38c), consensus (40c)
PremiumThe Fly
Verrica Pharmaceuticals reports Q1 adjusted EPS (38c), consensus (40c)
2d ago
VRCA
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
PremiumPress Releases
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
2d ago
VRCA
VRCA Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
VRCA Upcoming Earnings Report: What to Expect?
4d ago
VRCA
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
PremiumPress ReleasesVerrica Pharmaceuticals to Present at Upcoming Investor Conferences
6d ago
VRCA
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
PremiumPress Releases
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
7d ago
VRCA
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
PremiumPress Releases
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
1M ago
VRCA
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
PremiumPress Releases
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
2M ago
VRCA
Verrica announces YCANTH receives new chemical entity status
PremiumThe Fly
Verrica announces YCANTH receives new chemical entity status
2M ago
VRCA
Verrica Pharmaceuticals price target raised to $13 from $12 at H.C. Wainwright
PremiumThe Fly
Verrica Pharmaceuticals price target raised to $13 from $12 at H.C. Wainwright
2M ago
VRCA
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
PremiumPress Releases
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
3M ago
VRCA
Verrica Pharmaceuticals reports Q4 EPS (53c), consensus (53c)
PremiumThe FlyVerrica Pharmaceuticals reports Q4 EPS (53c), consensus (53c)
3M ago
VRCA
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
PremiumPress Releases
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
3M ago
VRCA
VRCA Earnings this Week: How Will it Perform?
PremiumPre-Earnings
VRCA Earnings this Week: How Will it Perform?
3M ago
VRCA
Verrica Pharmaceuticals (NASDAQ:VRCA) Is Egging on Contrarian Options Traders
PremiumMarket News
Verrica Pharmaceuticals (NASDAQ:VRCA) Is Egging on Contrarian Options Traders
3M ago
VRCA
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
PremiumPress Releases
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
3M ago
VRCA
Verrica Pharmaceuticals files lawsuit against Dormer Laboratories
PremiumThe Fly
Verrica Pharmaceuticals files lawsuit against Dormer Laboratories
3M ago
VRCA
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
PremiumPress Releases
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
4M ago
VRCA
Verrica Pharmaceuticals receives permanent J-Code for YCANTH from CMS
PremiumThe FlyVerrica Pharmaceuticals receives permanent J-Code for YCANTH from CMS
4M ago
VRCA
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
PremiumPress Releases
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
4M ago
VRCA
Verrica Pharmaceuticals announces last patient dosed in Phase 2 trial of VP-315
PremiumThe Fly
Verrica Pharmaceuticals announces last patient dosed in Phase 2 trial of VP-315
4M ago
VRCA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >